Weekly Analysts’ Ratings Updates for ProQR Therapeutics (PRQR)

ProQR Therapeutics (NASDAQ: PRQR) recently received a number of ratings updates from brokerages and research firms:

• 6/26/2026 – ProQR Therapeutics had its price target lowered by Chardan Capital from $4.00 to $3.00. They now have a “buy” rating on the stock.
• 6/26/2026 – ProQR Therapeutics had its price target lowered by JonesTrading from $11.00 to $10.00. They now have a “buy” rating on the stock.
• 6/23/2026 – ProQR Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/8/2026 – ProQR Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/27/2026 – ProQR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/22/2026 – ProQR Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/16/2026 – ProQR Therapeutics was downgraded by Wall Street Zen from “hold” to “strong sell”.

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.